Christopher E. Eso
PresidentMr. Christopher E. Eso, also known as Chris, serves as Member of Advisory Board at Arboretum Ventures LLC since 2026. He is President of Minimed Group, Inc. Mr. Eso is a Vice President of Corporate Development at Medtronic, specifically covering the Cardiac and Vascular Group business units, including Cardiac Rhythm and Heart Failure (CRHF), Coronary and Structure Heart (CSH) and Aortic, Peripheral Vascular and endoVenous (APV). He was Member of Industry Advisory Board at Flare Capital Partners until July 2026. Mr. Eso joined Medtronic as the Senior Manager of Business Development in August of 2011. He oversaw Medtronic's global inorganic growth strategies and opportunities for Coronary business and was promoted in June of 2012 to expand his Business Development responsibilities to include the Renal Denervation business. In April of 2013, Mr. Eso was promoted to Director, overseeing Business Development functions and leading a team of professionals. In September of 2014, he was promoted to Senior Director of Business Development for the Coronary and Structural Heart business unit at Medtronic and in February of 2016, he was promoted to Vice President of Corporate Development. Mr. Eso is an Investment Advisor at Medical Technology Venture Partners. Mr. Eso served as a Vice President of Business Operations at Peregrine Pharmaceuticals Inc. since joining in January 2009. Previously, he served as a Manager of Corporate Development and Vice President of Business Operations at Agilent Technologies, where he helped execute strategic transactions across all businesses, including acquisitions, partnerships and alliances, joint ventures, in-licensing and investments and divestitures. Prior to joining Agilent Technologies, Mr. Eso served as a Director of Corporate Development at Peregrine Pharmaceuticals, from August 2007 to February 2008, where he was instrumental in achieving the first Wall Street security analyst coverage. Previously, Mr. Eso served as a Manager of Corporate Development, Senior Investor Relations Analyst and Vice President of Business Operations at Watson Pharmaceuticals. Earlier in his career, Mr. Eso held positions of increasing responsibility at various companies, including Allergan and the Professional Golfers' Association (PGA). He has transaction experience including structuring, negotiating and completing various strategic transactions, on a global basis. Mr. Eso has years of professional experience, of increasing responsibilities, primarily in business and corporate development, strategic planning, project management and external relations, with more than nine years specifically in the life sciences and pharmaceutical industries. Mr. Eso holds a B.A. in Communications and Public Relations from California State University and an M.B.A. from Concordia University.
Positions
- Company NameMiniMed Group, Inc.Stock CodeMMEDPositionPresidentColleagues
- QTQue Thanh DallaraCEO & Director
- KEKevin E. LoftonIndependent Chair of Board
- CJChad J. SpoonerExecutive VP & CFO
- ADAli DianatyExecutive VP and Chief Product & Technology Officer
- GCGillian ChandrasenaSenior VP & Chief Human Resources Officer
- TATimothy Alan WicksIndependent Director
- GAGlenn Andrew EisenbergIndependent Director
- DKD. Keith GrossmanIndependent Director
